US-based Respicardia has unveiled six month results from the remede system pilot study, the first prospective, multi-center, global trial to treat central sleep apnea (CSA). The remede system delivers electrical pulses to one of the ...
Tags: Respicardia, Remede System
Respicardia, a US-based developer of implantable therapies, has announced the enrollment of the first patients in the pivotal trial to evaluate the remede system in patients with central sleep apnea (CSA). The Respicardia pivotal trial is ...
Tags: Respicardia, Patient Enrollment
Respicardia, a US-based implantable therapies developer, has received approval from the US Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) to begin the pivotal trial of remedē System. The trial will ...
Tags: Respicardia, therapies developer